Teva Pharmaceutical Industries and University College London (UCL) have started a brain-imaging study to uncover a new approach in neurodegenerative disease.  The two-year study, which will be carried out in 20 patients, uses PET imaging to look at microglia cells in the central nervous system (CNS). {read more here}